Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BR-DA02
- Development stage
- Preclinical
- Lead developer
- BlueRock Therapeutics
- Modality
- Embryonic Stem Cells → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intracerebral (surgical Implantation)
01
Overview
BR-DA02 is an investigational cell therapy developed by BlueRock Therapeutics for the treatment of Parkinson's disease. It consists of dopaminergic neuron progenitor cells, designed to replace the dopamine-producing neurons lost in Parkinson’s disease. The therapy involves implanting these neuron precursors, derived from pluripotent stem cells (likely human embryonic stem cells), into the brain, where they are intended to mature into functional dopamine neurons and potentially restore both motor and non-motor function in patients. As of March 2025, BR-DA02 remains in preclinical development with its primary indication being Parkinson’s disease within the therapeutic area of nervous system diseases[1][4].
Beyond the preview
Go deeper on BR-DA02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BR-DA02.